In this Issue:
Evolocumab helps high-risk patients reach lipid targets
Evolocumab reduces Lp(a) levels
CABG vs PCI: a meta-analysis
Medical therapy ± PCI
Lp(a) levels and residual vascular risk
Coffee consumption and CV disease
Obesity and CV risk
Prolactin levels and mortality
Radio-frequency ablation as primary management of VT
Please login below to download this issue (PDF)